---
document_datetime: 2025-04-11 10:26:17
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/moventig-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: moventig-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.497336
conversion_datetime: 2025-12-24 17:27:31.683634
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Moventig

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10317 /202409  | Periodic Safety Update EU Single assessment - naloxegol                                                                                                                                                                                                                                                                                                                  | 10/04/2025                          | n/a                                         |                                  | PRAC Recommendation - maintenance |
| II/0043              | Submission of the final report from the PASS study D3820R0008 listed as a category 3 study in the RMP. This is a US post-marketing, comparative, observational study to evaluate the cardiovascular safety of Naloxegol in patients with non-cancer pain in comparison to other treatments for opioid induced constipation. The RMP version 9.0 has also been submitted. | 28/11/2024                          | n/a                                         |                                  |                                   |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                   |            |            |                        |                                                                    |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------|
| IB/0046             | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                                                                                                        | 27/11/2024 |            | SmPC, Labelling and PL |                                                                    |
| IAIN/0045           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                      | 17/09/2024 |            | Annex II and PL        |                                                                    |
| T/0044              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                             | 14/03/2024 | 15/04/2024 | SmPC, Labelling and PL |                                                                    |
| PSUSA/10317 /202309 | Periodic Safety Update EU Single assessment - naloxegol                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/04/2024 | n/a        |                        | PRAC Recommendation - maintenance                                  |
| II/0039             | Update of sections 4.2 and 4.4 of the SmPC based on real-world data from non-interventional studies (NACASY, KYONAL and MOVE studies), post- marketing data, and literature on the use of naloxegol in OIC patients with cancer-related pain. The Package Leaflet is updated accordingly. The RMP version 8.2 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC. C.I.6.a - Change(s) to therapeutic indication(s) - | 09/11/2023 | 11/12/2023 | SmPC and PL            | Please refer to Scientific Discussion 'Moventig H/C/002810/II/0039 |

<div style=\"page-break-after: always\"></div>

|                     | modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10317 /202209 | Periodic Safety Update EU Single assessment - naloxegol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 14/04/2023 | n/a | PRAC Recommendation - maintenance |
| IB/0041/G           | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation | 24/03/2023 | n/a |                                   |
| II/0038             | Submission of an updated RMP version 7.2 proposing the cancellation of the cat. 3 study (D3820R00009:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 07/07/2022 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | in selected European populations), following the assessment of MEA 006.11. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                     |            |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10317 /202109 | Periodic Safety Update EU Single assessment - naloxegol                                                                                                                                                                                                                                                                                                                                                       | 07/04/2022 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0034             | Submission of the final report from the observational Post Authorization Safety Study (PASS)- Drug Utilisation in Selected European Populations (D3820R00006), listed as a category 3 study in the Risk Management Plan (RMP). The RMP version 7.1 is accepted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 13/01/2022 | n/a | This variation concerns the final study report of the observational Post-authorization Safety Study (PASS) D3820R00006, to describe the utilization of naloxegol within a cohort of adult patients with opioid induced constipation (OIC). This study data provided insights into the demographics of naloxegol users, the utilisation of naloxegol in the general population (United Kingdom, Norway, Sweden and Germany) population with contraindications, potential off- label use, and the use in vulnerable/special populations (patients aged â‰¥65 years; pregnant; patients with prior cardiovascular disease; patients with prior renal or hepatic impairment; patients with concurrent methadone use; and patients with concurrent use of cytochrome P450 [CYP] 3A inhibitors/inducers or P-glycoprotein [Pgp] modulators). Overall, no new safety concerns were raised in this study. The RMP is updated accordingly (version 7.1) to remove |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                 | reference to study D3820R00006.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0035             | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                                                                                                                                                                                                                                                                                                                                                                                                                | 10/01/2022 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0037             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/12/2021 | 16/12/2022 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10317 /202009 | Periodic Safety Update EU Single assessment - naloxegol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 09/04/2021 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0029/G           | This was an application for a group of variations. Submission of an updated RMP version 6.1 in order to update the list of safety concerns. C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 04/09/2020 | n/a        |                 | In this group of variations the MAH updated the list of safety concerns in line with recommendations given in GVP Module V and reclassified 'GI perforation' as an important identified risk in order to implement the outcomes of the PRAC recommendation given in EMEA/H/C/PSUSA/00010317/201809 and following the PI amendments undertaken in this PSUR. The MAH also took the opportunity to include updated exposure data, updated analyses of the safety concerns and preliminary results from the additional pharmacovigilance activities. |
| PSUSA/10317 /201909 | Periodic Safety Update EU Single assessment - naloxegol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 17/04/2020 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| IAIN/0031   | B.II.g.3 - Deletion of an approved change management protocol related to the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 13/11/2019   | n/a        |                                  |                                                                                                                                                                                                                                                                        |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0030/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - | 18/10/2019   | 09/10/2020 | Annex II and PL                  |                                                                                                                                                                                                                                                                        |
| R/0028      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 25/07/2019   | 23/09/2019 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Moventig in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

<div style=\"page-break-after: always\"></div>

| PSUSA/10317 /201809   | Periodic Safety Update EU Single assessment - naloxegol                                                                                                                                                                                                                                                                                                                                                                                                                          | 26/04/2019   | 20/06/2019   | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10317/201809.   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0027/G             | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of | 13/02/2019   | 20/06/2019   | SmPC and PL            |                                                                                                                                              |
| PSUSA/10317 /201803   | Periodic Safety Update EU Single assessment - naloxegol                                                                                                                                                                                                                                                                                                                                                                                                                          | 18/10/2018   | 12/12/2018   | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10317/201803.   |
| IB/0025               | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                   | 23/10/2018   | 20/06/2019   | SmPC, Labelling and PL |                                                                                                                                              |
| IB/0024               | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g.                                                                                                                                                                                                                                                                                                                                                                                 | 07/08/2018   | 12/12/2018   | SmPC, Labelling and    |                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                     | tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            | PL                     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| T/0023              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 02/07/2018 | 23/07/2018 | SmPC, Labelling and PL |                                   |
| PSUSA/10317 /201709 | Periodic Safety Update EU Single assessment - naloxegol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12/04/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0021             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 29/01/2018 | 23/07/2018 | SmPC                   |                                   |
| IB/0020/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - | 20/12/2017 | 23/07/2018 | Annex II and PL        |                                   |

<div style=\"page-break-after: always\"></div>

|                     | Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                |            |            |                        |                                                                                                                                            |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10317 /201703 | Periodic Safety Update EU Single assessment - naloxegol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/10/2017 | 08/12/2017 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10317/201703. |
| IAIN/0019/G         | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 07/12/2017 | 23/07/2018 | SmPC, Labelling and PL |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IB/0016   | - Submission of a new/updated or deletion Ph. Eur. TSE Certificate of Suitability - Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 18/10/2017   | n/a   | B.III.1.z of variation   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|--------------------------|
| IA/0017/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch                                                                                                                                                                                                                                                                                                                                                                                                                             | 09/10/2017   | n/a   | size                     |
| IA/0015/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 05/07/2017   | n/a   |                          |

<div style=\"page-break-after: always\"></div>

| N/0013              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                          | 21/04/2017   | 08/12/2017   | Labelling and PL       |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------|
| PSUSA/10317 /201609 | Periodic Safety Update EU Single assessment - naloxegol                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 06/04/2017   | n/a          |                        | PRAC Recommendation - maintenance |
| T/0011              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 02/09/2016   | 30/09/2016   | SmPC, Labelling and PL |                                   |
| PSUSA/10317 /201603 | Periodic Safety Update EU Single assessment - naloxegol                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 29/09/2016   | n/a          |                        | PRAC Recommendation - maintenance |
| II/0007             | Update of sections 4.2 and 5.2 of the SmPC and section 3 of the PL, to provide information about the use of crushed tablets mixed in water and administered orally or via nasogastric tube. In addition, the Marketing authorisation holder (MAH) took the opportunity to combine the SmPCs for 12,5 mg and 25 mg and to bring the PI in line with the latest QRD template version 9.1. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 28/04/2016   | 30/09/2016   | SmPC, Annex II and PL  |                                   |
| PSUSA/10317 /201509 | Periodic Safety Update EU Single assessment - naloxegol                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14/04/2016   | n/a          |                        | PRAC Recommendation - maintenance |
| II/0009             | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                                                                                                                                                                                                                                                       | 07/04/2016   | n/a          |                        |                                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0008/G   | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate already approved manufacturer   | 15/01/2016   | n/a   | from an   |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------|
| IA/0006/G     | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate already approved manufacturer                                                                                                                                                                                                                                                                                         | 17/12/2015   | n/a   | from an   |
| II/0003       | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 10/12/2015   | n/a   |           |

<div style=\"page-break-after: always\"></div>

| IG/0633             | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                 | 09/12/2015   | n/a   |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10317 /201503 | Periodic Safety Update EU Single assessment - naloxegol                                                                                                                                                                                                                                                                                                                                                         | 08/10/2015   | n/a   | PRAC Recommendation - maintenance |
| IB/0001/G           | This was an application for a group of variations. B.II.g.5.b - Implementation of changes foreseen in an approved change management protocol - Requires further supporting data B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition B.I.c.z - Container closure system of the AS - Other variation B.I.c.z - Container closure system of the AS - Other variation | 24/03/2015   | n/a   |                                   |